Nov 16, 2026 10:12 PM
Updated Nov 16, 2026 10:23 PM
Bayer Leverkusen is moving swiftly to lock down the Algerian international, securing a long-term future without a release clause to ward off interest from European giants like PSG.
Bayer Leverkusen is on the verge of securing Ibrahim Maza's future, with the Algerian international expected to sign a new contract until June 2031.
Speaking on Sky Sport Germany's latest show, transfer journalist Florian Plettenberg revealed that negotiations are approaching their conclusion and that an agreement could be finalised within the next few days.
"Now he's first extending his contract on better terms until 2031. It could happen very quickly now, within the next few days."
The new deal would improve Maza's financial terms and extend his existing contract by another year. Crucially, the agreement is also expected to contain no release clause, allowing Leverkusen to retain control over any future transfer.
Related stories
Leverkusen Move Quickly To Protect One Of Their Most Valuable Players
Maza's rise has not gone unnoticed across Europe.
Paris Saint-Germain previously explored the possibility of bringing the 20-year-old to France, with the French champions identifying him as an interesting addition to their midfield.
However, those discussions failed to produce an agreement, and PSG eventually withdrew their interest.
For the Bundesliga club, the situation has only reinforced the importance of securing Maza on improved terms.
The Algerian has become one of the club's most important young players since arriving from Hertha Berlin in 2025, and his performances have significantly strengthened his standing within the squad.
While his existing contract already runs until 2030, extending it without including a release clause would put Bayer in a considerably stronger position ahead of future transfer windows.
It would also send a clear message to interested clubs: Leverkusen are not preparing to negotiate Maza's departure.
Maza's Extension Is A Significant Win For Bayer's Project
The Werkself have experienced considerable changes since Florian Wirtz's departure, with the club rebuilding its attacking department around younger players.
Maza has been one of the main beneficiaries of that transition, establishing himself as a regular under Carles Martínez and assuming greater responsibility during an inconsistent start to the campaign.
At just 20, he remains some distance from reaching his full potential.
That is precisely why completing this extension matters.
Leverkusen are not simply protecting a valuable asset. They are securing another period of stability for a player who could become one of the central figures in the club's next generation.
There is also an important financial consideration.
Having previously seen how quickly the market for young attacking midfielders can escalate, Bayer would be taking a sensible step by addressing Maza's contract before interest intensifies further.
An agreement without a release clause would ensure that any future departure takes place on the club's terms rather than at a predetermined price.
Bayer Can Plan Ahead Without Rushing Another Departure
Leverkusen are already monitoring Borussia Mönchengladbach youngster Wael Mohya, who is viewed as a potential long-term option in attacking midfield.
That interest demonstrates the club's willingness to prepare for the future, but it does not mean Maza needs to leave anytime soon.
Quite the opposite.
After losing Wirtz, Leverkusen have had to rebuild important parts of their team. Allowing Maza to continue developing alongside Malik Tillman and the club's other young attacking players offers the opportunity to establish greater continuity.
Maza may eventually attract an offer too significant to ignore, particularly if he continues progressing.
For now, however, there is little reason for Bayer to accelerate that process.
The proposed extension rewards a player who has justified the club's investment and gives Leverkusen stronger negotiating leverage without forcing an immediate decision over his long-term ambitions.
With an agreement reportedly just days away, Bayer are close to completing an important piece of business that could prove as valuable as any new signing.
From here, the stage only gets bigger.
Comments
Powered by RoundtableAn AI/DeFi-powered Enterprise Media Operating System. Learn more at Roundtable.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy



